Target intelligence / Profile preview

microRNA 648 (miR-648 (or hsa-miR-648))

Target
miR-648 (or hsa-miR-648)
Molecular classification
microRNA, Small non-coding RNA, Regulatory RNA
01

Overview

microRNA 648 (miR-648) is a small, non-coding RNA molecule found in humans and categorized as a microRNA. It is encoded within the first intron of the MICAL3 gene and transcribed together with this host gene under the regulation of the PAX5 transcription factor. miR-648 functions primarily by binding to complementary sequences in the 3′ untranslated region (UTR) of target mRNAs, such as endothelin-1 (ET-1), leading to downregulation of target gene expression through mRNA degradation or inhibition of translation. In endothelial cells, miR-648 plays a role in the posttranscriptional regulation of ET-1, a vasoactive peptide involved in pulmonary hypertension, particularly in sickle cell anemia. Downregulation of miR-648 has been linked with increased ET-1 levels and disease progression in these contexts. Like other microRNAs, miR-648 is not a protein, receptor, enzyme, or transporter, but instead is a regulatory RNA that modulates gene expression posttranscriptionally.

Other names
hsa-mir-648MIRN648MIR648
02

Mechanism of action

RNA-induced silencing of target mRNAs, primarily through binding to complementary sequences in the 3′ UTR of target mRNAs, such as endothelin-1 (ET-1), leading to downregulation of target gene expression via mRNA degradation or inhibition of translation.

03

Biological functions

Posttranscriptional gene regulationmRNA degradationInhibition of translationRegulation of endothelin-1 (ET-1) expression
04

Disease associations

Pulmonary hypertensionSickle cell anemia (as related to pulmonary hypertension)Vascular remodeling (indirect, via ET-1 regulation)Other (potential roles in other diseases not fully mapped)
05

Safety considerations

Modulating miRNA functions can broadly affect gene expression networks and may result in off-target effects and unanticipated changes in multiple cellular pathwaysNo direct clinical safety concerns published for miR-648 modulation specifically
06

Biomarkers

miR-648 expression levels (potential biomarker in pulmonary hypertension/SCA patients)

Beyond the preview

Go deeper on microRNA 648 (miR-648 (or hsa-miR-648)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA 648 (miR-648 (or hsa-miR-648)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call